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Abstract 
Background and Aims: Latitudinal gradient effect is described for several autoimmune 
diseases including celiac disease in the United States. However, the association 
between latitude and global celiac disease prevalence is unknown. We aimed to explore 
the association between latitude and serology-based celiac disease prevalence through 
meta-analysis. 
Methods: We searched MEDLINE, Embase, Cochrane, and Scopus databases from 
their beginning through June 29, 2018, to identify screening studies that targeted a 
general population sample, used serology-based screening tests, and provided a clear 
location from which we could assign a latitude. Studies were excluded if sampling was 
based on symptoms, risk factors, or referral. Study selection and data extraction were 
performed by independent reviewers. The association measures between latitude and 
prevalence of serology-based celiac disease were evaluated with random-effects meta-
analyses and meta-regression. 
Results: Of the identified 4,667 unique citations, 128 studies were included, with 155 
prevalence estimates representing 40 countries. Celiac disease was more prevalent at 
the higher latitudes of 51º to 60º (relative risk, 1.62; 95% CI: 1.09-2.38) and 61º to 70º 
(relative risk, 2.30; 95% CI: 1.36-3.89) compared with the 41º to 50º reference level. No 
statistically significant difference was observed in lower latitudes. When latitude was 
treated as continuous, we found statistically significant association between CD 
prevalence and latitude overall in the world (RR=1.03, 95% CI: 1.01 – 1.05) and 
subregional analysis of Europe (RR=1.05, 95% CI: 1.02 – 1.07) and North America 
(RR=1.1, 95% CI: 1.0 – 1.2). 
Conclusions: In this comprehensive review of screening studies, we found that higher 
latitude was associated with greater serology-based celiac disease prevalence. 
 
Keywords: sprue; serum; tissue transglutaminase; epidemiology  
Introduction 
Celiac disease (CD) is a prevalent autoimmune disease triggered by ingested gluten. It 
is seen mostly in people of European, North African, and Middle Eastern descent. CD 
prevalence is highly heterogeneous1, 2. Geoepidemiology of CD can provide insight into 
pathogenesis and risk factors responsible for its distribution and increasing incidence3. 
Variations in prevalence among populations with similar human leukocyte antigen (HLA) 
predisposing allele frequencies and genetic backgrounds point to environmental factors 
that contribute to disease pathogenesis. Previous studies have shown a correlation 
between gluten consumption and HLA haplotype frequencies that predispose persons 
to CD4-6. A large part of the variation in worldwide prevalence has yet to be explained.  
 
Increasing autoimmunity in higher geographic latitudes has been reported for multiple 
sclerosis7, rheumatoid arthritis8, 9, and inflammatory bowel disease10. These 
associations were linked to less solar exposure and resultant vitamin D deficiency that 
has been shown to predispose to autoimmune states in several diseases11, 12. A study 
using National Health and Nutrition Examination Survey data reported a South-North 
gradient of CD seroprevalence in the United States13. The gradient was statistically 
significant after adjustment for race/ethnicity, sex, age, and income13. The latitudinal 
association with worldwide CD prevalence is unknown. Therefore, we conducted a 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































extract the latitudinal and longitudinal coordinates, we used Google Maps to select the 
geographic "centroid" of the study area and the related latitude and longitude of 
locations. The variable latitude represents the distance of the study from the equator, in 
the southern or northern hemisphere. Reviewers [M.G.C, C.L.J-K., I.A.H.] evaluated the 
studies for methodological quality, using a tool that assesses internal and external 
validity in prevalence studies18 (Supplemental Material 3). 
Statistical Analyses 
For studies reporting prevalence by age groups (ie, adults and children), locations, or 
screening periods, we used each cohort as an independent unit for analysis because 
they contributed independent information. For studies examining the same population, 
we included only the most recent or inclusive study or studies with sequential test 
results, if applicable.  
 
Crude prevalence was determined as the proportion of positive cases to individuals 
screened. We then normalized the prevalence using log transformation and pooled it 
using the DerSimonian Laird random-effects methods19. Heterogeneity— the variation in 
study prevalence estimates between studies that is not due to sampling variability—was 
assessed with the I2 statistic20. Random-effects meta-regression was carried out to 
calculate the association for seroprevalence and latitude after control for predefined 
variables, including age group, year of screening, type of test used to diagnose cases, 
and study region21. Age was categorized as pediatric (0-18 years) and adult (>18 
years). Testing method was categorized into 1) sequential with IgA tTGA, AGA, or 
deamidated gliadin peptide (DGP) antibodies followed by EMA or only EMA testing or 2) 
IgA tTGA testing. Latitudes were categorized based on 10º increments from the 
equator. Latitudes from 0º to 20º were considered 1 category to increase the number of 
studies included in the category. A latitudinal level of 41º to 50º was set as the reference 
group to stabilize regression because most studies were conducted within this level. We 
conducted analyses using latitude and longitude as continuous variables in the 
regression model for each region and the world. We evaluated the relationship between 
sample size and prevalence estimates with the funnel plot using the log of the 
prevalence and Egger’s regression test of asymmetry22. We used Stata 15 command 
metareg to perform regression on study-level data and metan for pooled prevalence 
estimates. Two tailed P values less than .05 were considered statistically significant. 
Software Stata version 15.1 (StataCorp LLP, College Station, TX) was used for 
statistical analysis. A map with study locations colored to represent levels of prevalence 
was created using QGIS 3.12 (http://qgis.org). 
Results 
Of the identified 4,667 unique abstracts, we included 155 cohorts from 128 studies that 
represented 40 countries (Figure 1). The samples used for these cohorts were blood 
donors (n=26), convenience samples (n=5), and general population (n=124) 
(Supplemental Material 2). Most studies were from Europe, followed in frequency by 
Middle East and North Africa (Supplemental Material 4). Most of the studies from 
Europe and North America provided results based on sequential screening or EMA 
alone (92/124). Of the 155 cohorts, 65 were pediatric. Prevalence from 1980 through 
2016 was available (mean screening year, 2003; range, 1980-2016). Most studies with 
the screening year before 2000 were from Europe (32/37). Supplemental material 2 
provides details of the 128 studies with references included. All studies had low or 
moderate risk of bias (Supplemental Material 3).   
 
The worldwide prevalence estimate was 0.79% (95% CI: 0.71-0.88) with significant 
heterogeneity (I2=91.2%) (Table 1, Figure 2). After controlling for the screening test, age 
group, screening year, and region, the higher latitudes had a statistically significant 
association with higher CD seroprevalence (Table 2). The relative risk (RR) of CD was 
1.62 (95% CI: 1.09-2.38) in 51º to 60º latitudes and 2.30 (95% CI: 1.36-3.89) in 61º to 
70º latitudes compared with the reference level 41º to 50º (Table 2). Relative risk in 
lower latitude categories did not reach statistical significance (Table 2). Positive 
latitudinal association was observed in the sub-regional analysis of Europe. When 
latitude was treated as continuous, we found statistically significant association between 
CD prevalence and latitude overall in the world (RR=1.03, 95% CI: 1.01 -1.05) and in 
the sub-regional analysis of Europe (RR=1.05, 95% CI: 1.02 – 1.07) and North America 
(RR=1.1, 95% CI: 1.0 – 1.2) (Table 3, Supplemental Material 5 and 6). Longitude was 
not associated with global CD prevalence (RR=1.002, 95% CI: 0.998 - 1.005). All study 
locations are depicted on a world map in Figure 3 and referenced (Supplemental 
Material 7). 
 
The visual examination of the funnel plot depicting the log of the prevalence plotted 
against the estimated standard error showed funnel plot asymmetry with significance 
(Egger’s regression test, p < 0.05) indicating that smaller studies tended to have lower 
prevalence estimates (Supplemental Material 8).  
Discussion 
In this study, we found an overall increase in the risk of CD prevalence globally with 
increasing latitude after controlling for regions and covariates for study level differences. 
When latitudes were categorized into intervals of 10º latitudinal increments, an 
association was seen between CD prevalence and latitudes above 40⁰. In regions with 
lower latitudinal coordinates, North India and the Arabian Peninsula in the Northern 
Hemisphere and Brazil in the Southern Hemisphere were found to be high-prevalence 
regions. The higher latitudes were significantly associated with higher CD 
seroprevalence in the United States and Europe in regional analyses. The prevalence of 
CD varies widely across regions, likely because of differences in genetic and 
environmental factors. Overall, genetic inheritance explains 50% of susceptibility6 and 
among the genetic factors, HLA-DQ2 and HLA-DQ8 haplotypes are the major 
determinants in the pathogenesis of CD23. Increased predisposing HLA frequencies 
tend to aggregate in regions where the duration of historical wheat consumption is 
longer4, possibly contributing to higher prevalence rates in these regions. After Europe, 
studies from the region of the Middle East and North Africa provided most of the 
prevalence estimates included in the analyses.  
 
Genetic predisposition fails to explain differences among and within some regions in the 
world.  In India, although the CD predisposing HLA-DQ frequencies were similar in 
Northern, Northeastern and Eastern India, CD is reported to be more prevalent in 
northern regions where wheat intake is higher5. On the other hand, despite wheat 
consumption per capita being highest in North African and Middle Eastern countries, the 
North European regions still have the highest prevalence estimates in this current study. 
These observations point to combination of factors and unidentified elements that 
modify disease risk. 
 
Latitude is often used as a surrogate of environmental factors in geoepidemiologic 
studies. CD shares common mechanisms of antigen presentation and T-cell–mediated 
immune activation with multiple sclerosis7 and rheumatoid arthritis8, 9 whose geographic 
distributions show latitudinal association23, 24. The only study on latitude and CD to our 
knowledge is from the United States that is located between 20º and 50º north and 
showed a greater prevalence of CD with higher latitudes13. A candidate factor typically 
associated with the latitudinal coordinate that may have a role in causality is vitamin D–
effective solar UV radiation. Skin exposure to solar radiation at UVB wavelengths that is 
determined by the season and latitude is the major source of 25-hydroxyvitamin D 
levels in the body in the absence of supplementary intake25, 26. Evidence has shown the 
modulatory effect of vitamin D on the immune system through the inducement and 
maintenance of tolerogenic immune cells27, 28. Multiple sclerosis is one of the well-
defined autoimmune diseases with latitudinal association and the protective effect of 
vitamin D in multiple sclerosis has been extensively investigated12, 29, 30. The 
immunomodulatory effect of vitamin D towards immune tolerance was further supported 
by the association of incidence and disease activity with vitamin D levels in multiple 
sclerosis12, 30, inflammatory bowel diseases31, 32, rheumatoid arthritis33 and systemic 
lupus erythematosus34. Vitamin D deficiency in celiac disease, as a fat soluble vitamin in 
a malabsorptive condition, is common; however, its role in pathogenesis is not known35-
37.  
 
Latitude may be a proxy for socioeconomic status or infection with common viruses. 
Certain environmental pathogens such as enteroviruses38, 39 and adenoviruses40-42 have 
been shown to be associated with development of CD43. Socioeconomic status may 
result in differences in environmental conditions in complex ways including differential 
exposure to infections, vaccines, antibiotic use, microbial flora, and gluten consumption, 
but there are no conclusive data showing an association with socioeconomic status and 
celiac disease44-46. 
 
The gradient effect in rheumatoid arthritis and multiple sclerosis is observed to reverse 
or diminish in countries located at higher latitudes, such as Norway and Sweden7, 47. 
Namatovu et. al. found that childhood CD was more prevalent in the southern latitudes 
of Sweden than in its northern latitudes and attributed this pattern to differences in 
awareness and rates of yearly epidemics of viruses48. Environmental factors including 
cultural differences and infections may surpass the effect of latitude associated factors. 
We did not have finely delineated distributions of prevalence in latitudes above 60º to 
examine a similar trend in higher latitudes.   
This meta-regression analysis did not show a uniform distribution of latitudinal gradient 
of CD globally. The disease was prevalent between the latitudes of 20º and 30º. Located 
near this area, Saudi Arabia and Brazil have reported prevalence rates comparable to 
those of Northern Europe. Increased prevalence and younger age at presentation of 
rheumatoid arthritis are also observed in countries near the Northern Tropic 
(23°26′12.4″ north of the equator)8. This outcome was attributed to the developmental 
status of countries and to related environmental exposures such as infections. Despite 
having high HLA genotype frequencies and one of the highest rankings in per-capita 
wheat consumption, Iran had a reported prevalence that was not as high as Saudi 
Arabia, which is located in a lower latitude, or Western European countries (data from 
http://www.fao.org, accessed April 24, 2019). The reasons for this trend have yet to be 
explained.  
 
We estimated the worldwide celiac disease serum prevalence at 0.79% with substantial 
variation (95% CI: 0.71-0.88%, I2 = 91%). A previous CD study estimated a higher 
global prevalence1. Because a sequential testing strategy was shown to be more 
sensitive and specific49-52, we included screening results of sequential testing 53 or the 
more specific tTG test assay results rather than AGA or less specific tTG test assays54-
56, when available. Additionally, we used criteria that specified inclusion of population 
samples without risk factors. These differences may account for the lower prevalence 
estimation in our study compared with previous meta-analysis studies of global or 
regional prevalence1, 57. The other potential reason may be the overrepresentation of 
small studies as shown in the funnel plot as smaller studies tended to show lower 
prevalence estimates58-61. This phenomenon could also be due to the aggregation of the 
larger scale studies in more prevalent areas such as Europe and North America. 
Strengths 
The comprehensive nature of the systematic review of prevalence studies is a major 
strength of the present study. We included screening year and testing type in our 
regression analysis to accommodate for known factors associated with prevalence. We 
included only serum-based screening studies for 2 main reasons. First, CD may be 
clinically silent, and most cases are undiagnosed. Studies from Northern European 
regions report increased awareness of CD starting in earlier years62, 63. Yet, recent 
studies have showed that a substantial proportion of CD is undiagnosed in parts of the 
world where people of North African and Middle Eastern descent predominate1. 
Second, screening studies based on biopsy results tend to have low response rates, 
and it is difficult to standardize the results. Therefore, our analysis reflects disease 
prevalence that is independent of region-specific differences in awareness of CD. We 
included studies with sequential testing that included EMA because this test has been 
shown to have the highest sensitivity and specificity16, 17. Because sequential or EMA 
alone testing is more specific than IgA tTGA results, we controlled for the type of testing 
in our models. 
Limitations 
Our study has some limitations. The latitudes assigned to each location in the present 
study were not precise. We found considerable heterogeneity between studies. There is 
a possibility of bias caused by extreme prevalence estimates from small sample studies 
in higher and lower latitudes. CD is more prevalent in women, but we did not have 
enough data from all studies to include sex in the analysis. Some regions were not 
represented in our analysis, including Sub-Saharan Africa and Canada, because either 
no studies were available or met our inclusion criteria. Although HLA-DQ2 and HLA-
DQ8 are known major genetic determinants of CD, data for HLA haplotype distributions 
were too heterogeneous and were not available for most study locations. Moreover, the 
provided allele frequencies represented different allele haplotypes. Some of the 
reported HLA allele frequencies were of certain ethnic populations and minority groups, 
whereas CD prevalence for corresponding locations provided prevalence for 
Caucasians. Various studies used different commercial test assays with different 
cutoffs, and we regarded each test result as positive according to the reporting in 
respective studies. Some prevalence studies used blood donors and convenience 
sampling methods which may not always be considered representative of general 
population; however, we evaluated studies systematically for methodological quality 
including for assessment of representation of the general population. All included 
studies had low or moderate risk of study bias. 
Conclusions 
We found serology-based CD prevalence was greater in higher latitudes away from 
equator toward south and north, similar to associations observed in chronic autoimmune 
diseases. Further studies on candidate environmental factors that are latitude-
associated including vitamin-D effective UVB exposure, environmental pathogens, and 
countries’ developmental status will advance the understanding of factors responsible 
for geographical variation of CD prevalence.  
 
Figure Legend 
Figure 1. Flow Diagram of Identified Studies 
Figure 2. Forest Plot  
Figure 3. World map showing the distribution of the studies 
Supplemental Material 6. Scatter plot of log-transformed prevalence against latitude and 
fitted linear prediction. The area of each circle is inversely proportional to the variance of 
the prevalence of each study location. 
Supplemental Material 8. Funnel plot examining publication bias   
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Supplemental Material. Results of Univariate and Multivariate 
Random-Effects Regression a 
Variable Relative Risk (95% CI) P Value 
Unadjusted 
Latitude  1.01 (1.00 – 1.02) 0.071 
Multivariate regression without regions b 
Latitude 1.02 (1.00 – 1.03) 0.009 
Pediatric age group d    1.44 (1.07 – 1.94) 0.018 
Testing method, tTG e 1.59 (1.10 – 2.32) 0.015 
Screening year 1.01 (0.99 – 1.04) 0.356 
Multivariate regression with regions c 
Latitude 1.03 (1.01 – 1.05) 0.014 
Pediatric age group d 1.42 (1.03 – 1.96) 0.032 
Testing method e 1.53 (1.03 – 2.27) 0.034 
Screening year  1.02 (0.99 – 1.04) 0.228 
Europe (reference) 1  
North Africa and Middle East 1.541 (0.88 – 2.70) 0.228 
Latin America and the Caribbean 1.44 (0.61 – 3.42) 0.407 
Australia and New Zealand 2.40 (0.84 – 6.88) 0.101 
East and South Asia 0.90 (0.33 – 2.47) 0.831 
North America 0.96 (0.51 – 1.81) 0.909 
a Model includes log-transformed prevalence estimates as the dependent variable. 
b Model includes covariates of latitude, age group, screening year, and testing method. 
c Model includes covariates of latitude, age group, screening year, test type, and world regions.  
d Adult age group as reference  
e Sequential testing as reference 
 
 
Table 1. Prevalence Estimates for Individual Regions and Latitudinal Intervals 
Value No. of Cohorts (No. 
of Studies) 
Pooled Prevalence 
Estimate % (95% CI) 
I2,% 
World pooled estimate 155 (127) 0.79 (0.71-0.88) 91.2 
World region    
North Africa and Middle East 30 (27) 0.96 (0.74-1.23) 89.6 
Latin America and the Caribbean 13 (13) 0.51 (0.3-0.88) 89.8 
Australia and New Zealand 3 (3) 1.27 (1.02-1.57) NA 
Europe 91 (73)  0.83 (0.72-0.95) 90.4 
East and South Asia 7 (5) 0.45 (0.24-0.86) 94.9 
North America 11 (6) 0.57 (0.37-0.88) 95.1 
Latitudinal interval    
≤20º 9 (9) 0.55 (0.02-1.27) 92.9 
>20º to ≤30º 19 (17) 0.98 (0.7-1.36) 90.9 
>30º to ≤40º 34 (30) 0.58 (0.44-0.78) 92 
>40º to ≤50º 42 (36) 0.67 (0.55-0.81) 90 
>50º to ≤60º 37 (31) 0.99 (0.81-1.22) 90.8 
>60º to ≤70º 14 (13) 1.24 (0.99-1.54) 83.4 
Abbreviation: NA, not available. 
 
Table 2. Adjusted Relative Risk for Latitudinal Intervals  
Latitudinal Intervals No. of Cohorts Relative Risk (95% CI) 
≤20º 9 0.87 (0.29-2.66) 
>20º to ≤30º 19 0.95 (0.37-2.40) 
>30º to ≤40º 34 0.50 (0.25-1.02) 
>40º to ≤50º 42 1.0 (reference) 
>50º to ≤60º 37 1.62 (1.09-2.38)a 
>60º to ≤70º 14 2.30 (1.36-3.89)a 
aBold indicates statistical significance. 
Model includes covariates of age group, screening year, test type, and world regions, with log-
transformed prevalence estimates as the dependent variable. 
 
 
Table 3. Region-Specific and Global Latitudinal Coefficientsa  
Region Relative Risk (95% CI) P Value 
Worlda 1.03 (1.01-1.05) .014 
Europeb 1.05 (1.02-1.07) <.001 
North Americab 1.10 (1.00-1.20) .05 
North Africa and Middle Eastb 1.00 (0.90-1.01) .11 
Latin America and the Caribbeanb 1.01 (0.93-1.10) .41 
East and South Asiab 0.88 (0.59-1.30) .36 
a Model includes covariates of age group, screening year, test type, and world regions, with log-
transformed prevalence estimates as the dependent variable. 
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Supplemental Material 2. Characteristics of Included Studies 
Study Year of 
screeni
ng 














 2008 Sweden Orebro 59.30 20-99 Blood donors  tTGA EMA 400 5 0.0125 
Abu-Zeid, 20142 2008 UAE Al Ain 24.21 16-70 Convenience sampling Prenuptial 
examination 
tTGA   EMA 1197 14 0.0117 
Abu-Zekry, 20083 2004 Egypt Cairo 30.05 0-18 Convenience sampling General outpatient 
clinic 
tTGA   EMA 1500 16 0.0053 
Agardh, 20044 2000 Sweden Malmo 55.61 2-4 General population  tTGA EMA 652 19 0.0291 
Agardh, 2007
5
 2007 Sweden Malmo 55.61 19-81 General population  tTGA NA 398 6 0.0151 
Agardh, 20096 2000 Sweden Lund 55.78 50-64 General population Female patients tTGA NA 6481 60 0.0093 
Akbari, 2006_1
7
 2004 Iran  Sari 36.33 18-66 General population  tTGA   EMA 1438 3 0.0021 
Akbari, 2006_2 2004 Iran  Kerman 30.29 18-66 General population  tTGA   EMA 1361 2 0.0015 
Al Hatlani,2015
8
 2014 Saudi Arabia Eastern Province, 
National Guard 
26.20 6-18 General population  tTGA   NA 1141 32 0.0280 
Al-Ajlan, 2016
9
 2013 Saudi Arabia Riyadh 24.77 20-60 General population  tTGA EMA 482 9 0.0187 
Alarida, 201110 2011 Libya El Beida 36.7 5-17 General population  tTGA   NA 2920 24 0.0146 
Alencar, 2012
11
 2004 Brazil San Paulo 23.55 18-65 Blood donors  tTGA   EMA 4000 14 0.0082 
Alessandrini, 2013_112 2005 Republic of San 
Marino 
Republic of San 
Marino 
43.94 6-14 General population  AGA EMA 4304 28 0.0033 
Alessandrini, 2013_2 2009 Republic of San 
Marino 
Republic of San 
Marino 
43.94 6-10 General population  tTGA EMA 788 14 0.0065 
Al-Hussaini, 201713 2016 Saudi Arabia Riyadh 24.8 6-15 General population  tTGA EMA 7932 116 0.0178 
Aljebreen, 2013_Al-Qaseem
14
 2008 Saudi Arabia Al-Qaseem 26.2 16-18 General population  EMA NA 252 8 0.0317 
Aljebreen, 2013_Aseer 2008 Saudi Arabia Aseer 19.26 16-18 General population  EMA NA 479 10 0.0209 
Aljebreen, 2013_Madinah 2008 Saudi Arabia Madinah 24.55 16-18 General population  EMA NA 436 8 0.0183 
Almazan, 201515 2012 Spain Granada 37.18 2-4 General population  tTGA NA 198 6 0.0303 
Almeida, 2013
16
 2011 Brazil Brasilia 15.77 60-92 General population  tTGA   EMA 946 1 0.0011 
Anderson, 201317 2006 Australia South East 
Australia 
34.66 20-97 General population  tTGA   EMA 2548 27 0.0106 
Antunes, 200218 1999 Portugal Braga 41.55 13-15 General population  tTGA EMA 536 5 0.0093 
Bahari, 2010
19
 2007 Iran  Sistan and 
Baluchestan 
Province 
29.47 17-65 Blood donors  tTGA   NA 1600 14 0.0088 
Bdioui, 2006
20
 2004 Tunisia Monastir 35.77 17-57 Blood donors  EMA tTGA 1418 2 0.0014 
Bonamiko, 2011
21
 2007 Italy  Rome 41.9 10-14 General population  tTGA EMA 4048 50 0.0124 
Borch, 2000
22
 2000 Sweden  Linkoping 58.41 35-85 General population  EMA NA 482 9 0.0187 
Canavan, 2011
23
 2001 UK Cambridge 52.21 45-76 General population  EMA tTGA 7550 88 0.0117 
Carlsson, 200124 1997 Sweden  Malmo 55.61 2-4 General population  AGA EMA 679 13 0.0191 
Castano, 2004
25
 2002 Spain Bizkaia, Cruces 43.29 <3 General population  tTGA   EMA 484 7 0.0145 
Catassi, 199426 1993 Italy Pesaro-Urbino 43.74 11-15 General population  AGA EMA 3351 20 0.0060 
Catassi, 2000
27
 1998 Italy Alghero 40.56 11-15 General population  AGA EMA 2096 19 0.0091 
Catassi, 201028 1989 USA Washington 
County, Maryland 
39.63 35-65 General population  tTGA   EMA 3511 16 0.0046 
Chin, 2009
29
  1995 Australia Busselton 33.39 20-79 General population  tTGA NA 3011 43 0.0143 
Choung, 2017
30
 2011 USA Olmsted County 44.02 18-50 General population  tTGA   EMA 30425 372 0.0111 
Cilleruelo, 200231 2000 Spain Madrid 40.42 10-12 General population  EMA NA 3378 15 0.0044 
Cook, 2000
32
 2000 New Zealand Christchurch 43.53 >18 General population  EMA NA 1064 13 0.0122 
Corraza, 199733 1997 Republic of San 
Marino 
Republic of San 
Marino 
43.94 18-87 General population  EMA NA 2237 4 0.0018 
Csizmadia, 1999
34
 1997 The Netherlands Zuid-Holland 51.99 2-4 General population  EMA NA 6127 75 0.0122 
da Conceicao-Machado, 2015
35
 2009 Brazil Salvador City, 
Bahia 
12.93 11-17 General population  tTGA NA 1213 7 0.0058 
Dalgic, 201136 2008 Turkey Turkey 39.25 6-17 General population  tTGA   EMA 20190 215 0.0106 
Demirceken, 2008
37
 2003 Turkey Ankara 39.56 2-18   Convenience sampling General outpatient 
clinic 
tTGA   EMA 1000 10 0.0100 
Denghani, 2013
38
 2013 Iran  Shiraz 29.59 6-12 General population  tTGA   NA 1500 30 0.0200 




tTGA   EMA 7660 26 0.0034 
El-Hadi, 200440 2002 UK Wales 51.83 18-22 General population  tTGA EMA 1000 6 0.0060 
Ertekin, 2005
41
 2005 Turkey Erzurum 39.9 6-17 General population  tTGA   NA 1263 11 0.0087 
Fabiani, 2004_Marche
42
 2001 Italy  Camerano, Marche 43.61 1-91 General population  tTGA EMA 1500 6 0.0040 
Fabiani, 2004_Sardinia 2001 Italy  Alghero, Sardinia 40.56 10-19 General population  tTGA EMA 2041 25 0.0122 
Farahmand, 2012
43
 2008 Iran  Tehran 35.7 7-18 General population  tTGA   NA 634 3 0.0047 
Fukunaga, 201744 2016 Japan Shimane 35.16 25-80 General population  tTGA   EMA 2008 0 0.0000 
Galvan, 2010
45
 2007 Cuba Pinar del Rio 22.42 3 General population  tTGA NA 595 7 0.0118 
Gandolfi, 200046 1998 Brazil Brasilia 15.77 18-61 Blood donors  AGA EMA 2045 4 0.0020 
Garcia Novo, 2007
47
 2002 Spain Madrid 40.42 18-65 General population  tTGA   NA 2215 11 0.0050 
Godfrey, 201048 2001 USA Olmsted County 44.02 50-88 General population  tTGA   EMA 16886 129 0.0076 
Gomez, 2001
49
 2000 Argentina La Plata, Buenos 
Aires 
34.92 16-79 General population  AGA EMA 2000 12 0.0060 
Guariso, 1997
50
 1995 Italy Padua 45.4 10-15 General population  AGA EMA 939 2 0.0021 
Gursoy, 200551 2004 Turkey Kayseri 38.73 20-59 Convenience sampling Routine examination 
for general medical 
reasons 
tTGA   NA 906 48 0.0530 
Handel, 201852 2015 Germany Leipzig 51.3 1-18 General population  tTGA EMA 2363 28 0.0118 
Hariz, 2007
53
 2004 Tunisia Ariana 36.86 7-13 General population  tTGA   EMA 6286 30 0.0048 
Hariz, 201354 2011 Tunisia Djerba 33.81 6-12 General population  tTGA EMA 2064 7 0.0034 
Henker, 2002_1
55
 1995 Germany Dresden 51.07 5-12 General population  EMA NA 3004 5 0.0017 
Henker, 2002_2 1995 Germany Dresden 51.07 17-64 Blood donors  EMA NA 4313 12 0.0028 
Hogen Esch, 2010
56
 1998 The Netherlands The Netherlands 52.24 2-4 General population  EMA NA 6127 75 0.0122 
Horwitz, 2015
57
 2012 Denmark Southwestern 
Copenhagen 
55.66 24-76 General population  tTGA NA 2297 13 0.0057 
Hovdenak, 199958 1999 Norway Bergen 60.58 18-67 Blood donors  AGA EMA 2069 8 0.0039 
Israeli, 2010
59
 2003 Israel Israel 31.91 18 Convenience sampling Military recruits tTGA NA 850 9 0.0106 
Ivarsson, 199960 1994 Sweden  Umea-North 
Sweden 
63.83 25-74 General population  AGA EMA 1894 10 0.0053 
Ivarsson, 201361 2010 Sweden  Sweden 59.34 12 General population  tTGA   EMA 5424 99 0.0183 
Jansen, 2018
62
 2013 The Netherlands Rotterdam 52.2 6 General population  tTGA EMA 4442 35 0.0079 
Johannsson, 200963 2007 Iceland  Akureyri 65.68 17-64 Blood donors  tTGA   NA 813 6 0.0074 
Karagiozoglou-Lampoudi, 
2013_N64 
2013 Greece Thessaloniki 40.62 2-6 General population  tTGA EMA 598 7 0.0117 
Karagiozoglou-Lampoudi, 
2013_NW 
2013 Greece Agrinio 38.62 2-6 General population  tTGA EMA 174 1 0.0057 
Karagiozoglou-Lampoudi, 
2013_S 
2013 Greece Herakleion 35.34 2-6 General population  tTGA EMA 308 0 0.0000 
Katz, 2011
65
 2011 USA Natrona County 42.86 >18 General population  tTGA EMA 3850 34 0.0088 
Khayyat, 201266 2010 Saudi Arabia Jeddah 21.49 14-78 Blood donors  tTGA NA 204 3 0.0147 
Kochhar, 2012
67
 2011 India Chandigarh 30.73 20-41 Blood donors  tTGA NA 1610 9 0.0056 
Kolho, 199868 1996 Finland Helsinki 60.18 NA General population  EMA NA 1070 11 0.0103 
Kondrashova, 2008
69
 2001 Russia Russian Karelia 
Region  
63.50 6-18 General population  tTGA EMA 1988 9 0.0045 
Korponay-Szabo, 1999
70
 1999 Hungary Budapest 47.49 3-6 General population  EMA NA 427 6 0.0141 
Korponay-Szabo, 200771 2005 Hungary Jasz-Nagykun-
Szolnok County 
47.23 6 General population  tTGA EMA 2690 33 0.0123 
Kratzer, 201372 2002 Germany Leutkirch  47.82 18-65 General population  tTGA NA 2157 17 0.0065 
Laass, 2015
73
 2006 Germany Germany 51.08 1-17 General population  tTGA NA 12741 106 0.0083 
Leja, 201574 2012 Latvia Latvia 56.90 24-74 General population  tTGA EMA 1444 5 0.0035 
Lohi, 2007_1
75
 1980 Finland Finland 62.98 30-95 General population  tTGA EMA 6993 76 0.0109 
Lohi, 2007_2 2001 Finland Finland 62.98 30-95 General population  tTGA EMA 6402 124 0.0194 
Maki, 2003
76
 1994 Finland Northern Finland, 
Oulu 
65.05 7-16 General population  tTGA EMA 4280 54 0.0126 
Mankai, 2006
77
 2003 Tunisia Sousse 35.83 16-63 Blood donors  AGA EMA 2500 7 0.0028 
Marine, 200978 2005 Spain Terrassa 41.56 30-40 Convenience sampling Workers in health 
department 
tTGA+EMA EMA 1868 8 0.0043 
Marine, 2011_1
79
 2007 Spain Catalonia 41.63 1-19 General population  tTGA NA 2994 38 0.0127 
Marine, 2011_2 2007 Spain Catalonia 41.63 19-99 General population  tTGA NA 3246 11 0.0034 
McMillan, 1996_180 1983 UK Belfast 54.53 15-64 General population  EMA NA 1206 19 0.0158 
Melo, 2006
81
 2002 Brazil San Paulo 23.55 18-45 Blood donors  tTGA EMA 3000 15 0.0050 
Menardo, 200682 2003 Italy  Carcare 44.55 13-90 General population  tTGA EMA 1002 13 0.0130 
Mestkula, 1998
83
 1996 Estonia Southern Estonia 57.94 9-15 General population  AGA EMA 487 0 0.0000 
Montesanti, 199684 1994 Italy Lucca 43.88 10-15 General population  AGA EMA 1073 4 0.0037 
Moura, 2012
85
 2009 Brazil Recife 8.06 18-30 Convenience sampling  tTGA EMA 683 5 0.0059 
Mustalahti, 2010_Finland86 2001 Finland Finland 62.98 30-93 General population  tTGA EMA 6403 128 0.0200 
Mustalahti, 
2010_Germany1990 
1990 Germany Ausburg 48.34 25-74 General population  tTGA EMA 4633 7 0.0015 
Mustalahti, 
2010_Germany2001 
2001 Germany Ausburg 48.34 25-74 General population  tTGA EMA 4173 11 0.0026 
Mustalahti, 2010_UKadults 1987 UK Northern Ireland 54.53 25-64 General population  tTGA EMA 4781 69 0.0144 
Mustalahti, 2010_UKchild 2000 UK Northern Ireland 54.53 12-15 General population  tTGA EMA 1975 17 0.0086 
Myleus, 2009_Lund
87
 2006 Sweden Lund 55.78 12 General population  tTGA EMA 3078 94 0.0305 
Myleus, 2009_Norrkoping 2006 Sweden Norrkoping 58.59 12 General population  tTGA EMA 912 25 0.0274 
Myleus, 2009_Norrtalje 2006 Sweden Norrtalje 59.76 12 General population  tTGA EMA 845 23 0.0272 
Myleus, 2009_Umea 2006 Sweden Umea 63.83 12 General population  tTGA EMA 1355 27 0.0199 
Myleus, 2009_Vaxjo 2006 Sweden Vaxjo 56.94 12 General population  tTGA EMA 1017 43 0.0423 
Nenna, 201388 2010 Italy  Rome 41.9 2-8 General population  tTGA EMA 5733 74 0.0129 
Not, 1998
89
 1996 USA Baltimore, 
Maryland 
39.3 19-48 Blood donors  tTGA EMA 2000 8 0.0040 
Nusier, 2010
90
 2006 Jordan Irbid City 32.56 6-10 General population  tTGA EMA 1985 16 0.0081 
Oliveira, 200791 2004 Brazil San Paulo 23.55 18-65 Blood donors  tTGA NA 3000 45 0.0150 
Pereira, 2006
92
 2001 Brazil Curitiba 25.42 20-62 Blood donors  tTGA EMA 2086 6 0.0029 
Pittschieler, 199693 1996 Italy  South Tyrol 46.7 18-82 General population  AGA EMA 4615 9 0.0020 
Pratesi, 2003
94





2012 India Tamil Nadu 12.26 18-100 General population  tTGA NA 8973 12 0.0013 
Ramakrishna, 2016_Haryana 2013 India Haryana 28.93 18-100 General population  tTGA NA 6209 76 0.0086 
Ramakrishna, 2016_Assam 2013 India Assam 26.14 18-100 General population  tTGA NA 8149 70 0.0122 
Ravikumara, 200796 2000 UK Avon, Southwest 
UK 
51.35 8 General population  tTGA EMA 5470 57 0.0104 
Remes-Troche, 2006
97
 2004 Mexico Mexico City  19.45 17-64 Blood donors  tTGA NA 1009 27 0.0268 
Ress, 2011
98
 1999 Estonia Tartu County 58.37 9-15 General population  tTGA NA 1160 5 0.0043 
Riestra, 200099 1998 Spain Langreo, Austrias 43.42 2-89 General population  AGA/NA EMA 1170 3 0.0026 
Roka, 2007
100
 2006 Greece Thessaly 39.56 18-80 General population  tTGA EMA 2230 4 0.0018 
Rostami, 1999101 1998 The Netherlands Arnhem, Nijmegen 51.92 18-100 Blood donors  EMA NA 1000 3 0.0030 
Rutz, 2002
102
 2000 Switzerland Canton of St Gallen 47.19 11-18 General population  tTGA EMA 1450 11 0.0076 
Saberi-Firouzi, 2008103 2004 Iran Shiraz 29.61 20-83 General population  tTGA EMA 1440 2 0.0014 
Sanders, 2003
104
 2001 UK South Yorkshire 53.51 16-91 General population  tTGA EMA 1200 12 0.0100 
Sardy, 2013105 2002 Hungary Budapest 47.49 - Blood donors  tTGA EMA 4155 25 0.0060 
Schweizer, 2004
106
 1997 The Netherlands Amsterdam, 
Doerinchem, 
Maastricht 
52.24 20-59 General population  tTGA EMA 1440 14 0.0090 
Sezgin, 2016
107
 2013 Turkey Mersin 36.83 18-82 General population  tTGA NA 1554 12 0.0077 
Shahbazkhani, 2003108 1999 Iran  Tehran 35.7 18-65 Blood donors  AGA EMA 2000 12 0.0060 
Shamir, 2002
109
 2001 Israel Israel 31.91 18-76 Blood donors  tTGA   EMA 1571 21 0.0134 
Sjoberg, 1999
110
 1997 Sweden  Linkoping 58.41 18-70 Blood donors  AGA EMA 1970 6 0.0030 
Szaflarska-Poplawska, 2009
111
 2009 Poland Bydgoszcz 53.12 7-10 General population  EMA NA 3235 25 0.0077 
Tatar, 2004
112
 2001 Turkey Ankara 39.96 18-65 Blood donors  tTGA   NA 2000 26 0.0130 
Tikkakoski, 2007113 2004 Finland Helsinki 60.18 18-64 General population  tTGA   EMA 1900 36 0.0189 
Tommasini, 2004
114
 2000 Italy Trieste 45.65 6-12 General population  tTGA   EMA 3188 33 0.0104 
Trevisiol, 1999115 1998 Italy Trieste 45.65 18-60 Blood donors  EMA NA 4000 10 0.0025 
Unalp-Arida, 2017_Midlat
116
 2014 USA Mid Latitude 37.5 20-100 General population  tTGA EMA 5392 21 0.0041 
Unalp-Arida, 2017_Midlat 2014 USA Mid Latitude 37.5 6-19 General population  tTGA EMA 1232 5 0.0039 
Unalp-Arida, 2017_North 2014 USA North 45 20-100 General population  tTGA EMA 6720 51 0.0024 
Unalp-Arida, 2017_North 2014 USA North 45 6-19 General population  tTGA EMA 1455 16 0.0351 
Unalp-Arida, 2017_South 2014 USA South 32 20-100 General population  tTGA EMA 5943 7 0.0015 
Unalp-Arida, 2017_South 2014 USA South 32 6-19 General population  tTGA EMA 1533 9 0.0046 
Utiyama, 2010
117
 2010 Brazil Mangueirinha 
Reserve 
25.56 2-86 General population  EMA NA 180 0 0.0000 
Vancikova, 2002
118
 2001 Czech Republic Prague 50.07 18-60 Blood donors  tTGA EMA 1312 6 0.0046 
Verkasalo, 2005119 2001 Finland  Finland  62.98 24-39 General population  tTGA EMA 2427 29 0.0119 
Vijgen, 2012
120
 2006 Belgium Belgium  46.7 1-19 General population  tTGA   EMA 1159 4 0.0035 
Vilppula, 2009121 2002 Finland  Paijat-Hame 61.05 52-74 General population  tTGA EMA 2815 44 0.0156 
Volta, 2001_1
122
 1992 Italy Campogalliano 44.69 12-25 General population  EMA NA 784 10 0.0128 
Volta, 2001_2 1992 Italy Campogalliano 44.69 25-65 General population  EMA NA 2699 10 0.0037 
Walker, 2010
123
 1998 Sweden  Kalix and 
Haparanda 
65.87 20-80 General population  tTGA   EMA 1000 18 0.0180 
Weile, 2001_Denmark
124
 2001 Denmark Denmark 55.62 18-65 Blood donors  AGA EMA 1573 4 0.0025 
Weile, 2001_Sweden 2001 Sweden Sweden 59.34 18-65 Blood donors  AGA EMA 1866 5 0.0027 
West, 2003
125
 1995 UK Cambridge 52.21 45-76 General population  EMA TGA 7550 91 0.0121 
Yap, 2015126 2014 Malaysia Kuala Lumpur 3.15 18-30 General population  tTGA   EMA 562 7 0.0125 
Yuan, 2017
127
 2013 China Nanchang 29 18-20 General population  DGP TGA 19778 72 0.0036 
Zunino, 2012128 2011 Italy Bergamo 45.7 19-62 Blood donors  tTGA EMA 18498 76 0.0041 
Abbreviations: AGA, amidated gliadin peptide antibody; DGP, deamidated gliadin peptide; EMA, endomysial antibodies; NA, not available; tTGA, tissue transglutaminase antibodies; UAE, United Arab Emirates; UK, United Kingdom; USA, United States of America.. 
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